Scinai Immunotherapeutics Ltd. (SCNI) — 6-K Filings

6-K Filings (39)

• Scinai Immunotherapeutics Holds Annual Shareholder Meeting — Dec 23, 2025 Risk: low
  On December 22, 2025, Scinai Immunotherapeutics Ltd. held its Annual Meeting of Shareholders. The total number of ordinary shares eligible to vote was 13,872,89
• Scinai Immunotherapeutics Reports 9-Month 2025 Results — Dec 2, 2025 Risk: medium
  On December 2, 2025, Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K to report its nine-month 2025 results. The company
• 6-K Filing — Nov 13, 2025
• Scinai Immunotherapeutics Secures Israel Innovation Authority Grant — Oct 6, 2025 Risk: low
  On October 6, 2025, Scinai Immunotherapeutics Ltd. announced it received a grant from the Israel Innovation Authority. This funding will be used to expand its f
• Scinai Immunotherapeutics Eyes Pincell srl Acquisition — Sep 22, 2025 Risk: medium
  Scinai Immunotherapeutics Ltd. announced on September 22, 2025, that it is anticipating the signing of an option agreement to acquire Pincell srl, an Italian bi
• Scinai Secures Up to $10M Equity Line with Yorkville — Sep 11, 2025 Risk: medium
  On September 10, 2025, Scinai Immunotherapeutics Ltd. entered into a Standby Equity Purchase Agreement with YA II PN, LTD. This agreement allows Scinai to sell
• Scinai Immunotherapeutics Files 6-K Report — Sep 2, 2025 Risk: low
  Scinai Immunotherapeutics Ltd. filed a Form 6-K on September 2, 2025, reporting information for the period ending June 30, 2025. The filing includes a press rel
• Scinai Immunotherapeutics Announces Funding and CDMO Growth — Jun 12, 2025 Risk: low
  On June 12, 2025, Scinai Immunotherapeutics Ltd. announced new funding and growth in its Contract Development and Manufacturing Organization (CDMO) business. Th
• Scinai Immunotherapeutics Gets Italian Clearance for Pincell Acquisition — Jun 5, 2025 Risk: medium
  On June 5, 2025, Scinai Immunotherapeutics Ltd. announced it has received Italian government clearance for its potential acquisition of Pincell S.r.l. This clea
• Scinai Immunotherapeutics Reports Q1 2025 Financials — Jun 2, 2025 Risk: low
  Scinai Immunotherapeutics Ltd. filed a Form 6-K on June 2, 2025, to report its Q1 2025 financial results, which were announced via press release on May 30, 2025
• Scinai Immunotherapeutics to Acquire Rare Disease Firm Pincell — Mar 27, 2025 Risk: medium
  On March 27, 2025, Scinai Immunotherapeutics Ltd. announced it has signed an option agreement to acquire Pincell, a rare disease company. This acquisition inclu
• Scinai Immunotherapeutics Licenses VAX-24 Flu Vaccine — Mar 24, 2025 Risk: low
  On September 26, 2024, Scinai Immunotherapeutics Ltd. granted exclusive global rights to its VAX-24 influenza vaccine candidate to an unaffiliated U.S. private
• Scinai Immunotherapeutics Secures $10M Equity Line — Mar 5, 2025 Risk: medium
  On March 5, 2025, Scinai Immunotherapeutics Ltd. announced a $10 million Standby Equity Purchase Agreement. This agreement provides the company with a flexible
• Scinai Immunotherapeutics Secures $10M Equity Line — Mar 4, 2025 Risk: medium
  On March 3, 2025, Scinai Immunotherapeutics Ltd. entered into a Standby Equity Purchase Agreement with YA II PN, LTD. This agreement allows Scinai to sell up to
• Scinai Immunotherapeutics Reports Q3 2024 Results — Nov 25, 2024 Risk: low
  Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on November 25, 2024, to report its Q3 2024 financial results and provi
• Scinai Immunotherapeutics Holds Annual Shareholder Meeting — Nov 22, 2024 Risk: low
  On November 21, 2024, Scinai Immunotherapeutics Ltd. held its Annual Meeting of Shareholders. The total number of ordinary shares eligible to vote was 3,411,983
• Scinai Immunotherapeutics Files October 6-K Report — Oct 15, 2024 Risk: low
  Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on October 15, 2024. This report is for the month of October 2024 and i
• Scinai Licenses Universal Flu Vaccine Candidate VAA437 — Sep 26, 2024 Risk: medium
  On September 26, 2024, Scinai Immunotherapeutics Ltd. entered into a license agreement with an unaffiliated U.S. private company. This agreement grants the Lice
• Scinai Immunotherapeutics Files 6-K Amendment — Sep 9, 2024 Risk: low
  Scinai Immunotherapeutics Ltd. filed an amendment (Amendment No. 1) to its Report on Form 6-K on September 9, 2024. This filing is an update for the month of Se
• Scinai Immunotherapeutics Regains Nasdaq Listing Compliance — Aug 29, 2024 Risk: low
  Scinai Immunotherapeutics Ltd. announced on August 29, 2024, that it has regained compliance with the Nasdaq Stock Market's listing requirements. This follows a
• Scinai Immunotherapeutics Restructures $29M Debt to Equity — Aug 21, 2024 Risk: medium
  On August 21, 2024, Scinai Immunotherapeutics Ltd. announced the closing of a Loan Restructuring Agreement with the European Investment Bank. This agreement con
• Scinai Secures $2M Equity Commitment — Aug 20, 2024 Risk: medium
  On August 20, 2024, Scinai Immunotherapeutics Ltd. announced a $2 million private equity commitment agreement with its largest existing shareholder. This agreem
• Scinai Immunotherapeutics Reports Q2 2024 Results — Aug 15, 2024 Risk: low
  On August 15, 2024, Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K to report its Q2 2024 financial results and provide
• Scinai Immunotherapeutics Restructures $29M Debt — Aug 13, 2024 Risk: medium
  On August 13, 2024, Scinai Immunotherapeutics Ltd. announced a significant debt restructuring with the European Investment Bank. The company converted approxima
• Scinai Immunotherapeutics Holds Shareholder Meeting — Aug 12, 2024 Risk: low
  On August 12, 2024, Scinai Immunotherapeutics Ltd. held an Extraordinary Meeting of Shareholders. The total number of ordinary shares eligible to vote was 3,349
• Scinai Immunotherapeutics Ltd. Updates Shareholder Meeting Proxy — Aug 5, 2024 Risk: low
  Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on August 5, 2024, to provide a Notice to Shareholders regarding change
• Scinai Immunotherapeutics Reports Promising Psoriasis Model Results — Jul 15, 2024 Risk: medium
  On July 15, 2024, Scinai Immunotherapeutics Ltd. announced promising in-vivo proof-of-concept results for its psoriatic human skin model. The company, formerly
• Scinai Gets Nasdaq Listing Extension — Jul 8, 2024 Risk: medium
  Scinai Immunotherapeutics Ltd. announced on July 3, 2024, that the Nasdaq Hearing Panel has granted an extension for the company to regain compliance with Nasda
• Scinai Immunotherapeutics Files Updated Business Presentation — Jun 14, 2024 Risk: low
  Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on June 14, 2024, to furnish an updated business presentation. The pres
• Scinai Immunotherapeutics Regains Nasdaq Bid Price Compliance — Jun 13, 2024 Risk: medium
  On June 7, 2024, Scinai Immunotherapeutics Ltd. announced it has regained compliance with Nasdaq's minimum $1.00 bid price requirement. The company is continuin
• Scinai Immunotherapeutics Faces Nasdaq Delisting Warning — May 28, 2024 Risk: medium
  Scinai Immunotherapeutics Ltd. received a Nasdaq staff determination letter on May 24, 2024, indicating non-compliance with shareholders' equity listing require
• Scinai Immunotherapeutics Files 2023 Annual Report — May 15, 2024 Risk: low
  Scinai Immunotherapeutics Ltd. announced on May 6, 2024, the publication of its fiscal year 2023 financial statements and the filing of its Annual Report on For
• Scinai Immunotherapeutics Faces Nasdaq Delisting, Plans Appeal — May 7, 2024 Risk: high
  Scinai Immunotherapeutics Ltd. announced on May 6, 2024, that it received a Nasdaq delisting notification. The company plans to appeal this decision and has app
• Scinai Immunotherapeutics Files Updated Business Presentation — Apr 25, 2024 Risk: low
  Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on April 25, 2024, to furnish an updated business presentation. The pre
• Scinai Immunotherapeutics Files Updated Business Presentation — Apr 16, 2024 Risk: low
  Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) has filed a Form 6-K on April 16, 2024, to provide an updated business presentation. Thi
• Scinai Immunotherapeutics Updates Corporate Presentation for January 2024 — Jan 18, 2024
  Scinai Immunotherapeutics Ltd. filed a 6-K on January 18, 2024, to provide an updated corporate presentation for January 2024. This presentation, furnished as E
• SCINAI IMMUNOTHERAPEUTICS UPDATES INVESTOR PRESENTATION — Jan 9, 2024
  Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) filed a 6-K on January 9, 2024, to provide an updated corporate presentation for January 2024. This presentation,
• Scinai Raises $1.69M from Warrants, CEO Sends Shareholder Letter — Jan 4, 2024
  Scinai Immunotherapeutics Ltd. filed a 6-K on January 4, 2024, announcing two key events: a letter to shareholders from CEO Amir Reichman and the closing of war
• Scinai Immunotherapeutics Raises $1.69M from Warrant Exercises — Jan 2, 2024
  Scinai Immunotherapeutics Ltd. announced on December 29, 2023, that it received $1.69 million in gross proceeds from the exercise of outstanding warrants. This

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX